Wall Street analysts expect that Moleculin Biotech Inc (NASDAQ:MBRX) will report ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Moleculin Biotech’s earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Moleculin Biotech reported earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year over year growth rate of 20%. The firm is scheduled to issue its next earnings results on Thursday, February 20th.

On average, analysts expect that Moleculin Biotech will report full-year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.38) to ($0.34). For the next fiscal year, analysts expect that the business will report earnings of ($0.44) per share, with EPS estimates ranging from ($0.48) to ($0.40). Zacks’ EPS averages are an average based on a survey of analysts that follow Moleculin Biotech.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

Several research firms have recently issued reports on MBRX. ValuEngine lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Maxim Group set a $3.00 price objective on Moleculin Biotech and gave the company a “buy” rating in a research note on Tuesday, August 20th. Zacks Investment Research lowered Moleculin Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Oppenheimer began coverage on Moleculin Biotech in a research note on Thursday, October 17th. They issued an “outperform” rating and a $2.00 price objective for the company. Finally, Roth Capital reaffirmed a “buy” rating on shares of Moleculin Biotech in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Moleculin Biotech presently has a consensus rating of “Hold” and an average target price of $4.33.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Moleculin Biotech by 235.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,680,010 shares of the company’s stock worth $3,350,000 after acquiring an additional 1,880,961 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Moleculin Biotech by 430.4% in the 2nd quarter. Renaissance Technologies LLC now owns 833,664 shares of the company’s stock valued at $1,042,000 after acquiring an additional 676,500 shares during the period. Millennium Management LLC purchased a new position in shares of Moleculin Biotech in the 3rd quarter valued at $237,000. BlackRock Inc. increased its holdings in shares of Moleculin Biotech by 134.8% in the 2nd quarter. BlackRock Inc. now owns 112,572 shares of the company’s stock valued at $141,000 after acquiring an additional 64,632 shares during the period. Finally, Morgan Stanley increased its holdings in shares of Moleculin Biotech by 151.7% in the 2nd quarter. Morgan Stanley now owns 31,411 shares of the company’s stock valued at $39,000 after acquiring an additional 18,933 shares during the period. 10.28% of the stock is owned by institutional investors and hedge funds.

Moleculin Biotech stock traded up $0.02 during midday trading on Monday, reaching $1.03. 127,781 shares of the stock traded hands, compared to its average volume of 1,205,668. The stock’s fifty day moving average is $1.07 and its 200-day moving average is $1.13. Moleculin Biotech has a 12 month low of $0.78 and a 12 month high of $3.15. The stock has a market cap of $45.65 million, a P/E ratio of -2.02 and a beta of 1.90. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.02.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Further Reading: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Moleculin Biotech (MBRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.